OX Receptor
OX receptor (orexin receptor) is a G-protein coupled receptor that is involved in the regulation of feeding behaviour.
Products Related to OX Receptor(52)
- GC13539SB-334867 hydrochlorideCAS: 249889-64-3Purity: >98.00%
SB-334867 hydrochloride is a potent, selective, and blood-brain barrier-permeable orexin-1 (OX1) receptor antagonist, with pK b of 7.4 for OX1 and pK i values of 5.4 and 5.3 for 5-HT2B and 5-HT2C, respectively.
- GC14887Orexin B (human)CAS: 205640-91-1Purity: >98%
Orexin B (human), a 28-residue peptides, has affinity for the OX1 and OX2 receptor with Ki of 420 and 36nM, respectively.
- GC16745Orexin B (mouse)CAS: 202801-92-1Purity: >98.50%
Orexin B (mouse) (Rat orexin B) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
- GC17992[Ala11,D-Leu15]-Orexin BCAS: 532932-99-3Purity: >98%
[Ala11,D-Leu15]-Orexin B is a potent and selective orexin-2 receptor (OX2) agonist.
- GC19220LemborexantCAS: 1369764-02-2Purity: >99.50%
Lemborexant (E2006) is an oral active diorexin receptor antagonist (DORA) and has been approved by the US Food and Drug Administration for the treatment of insomnia.
- GC19272Orexin 2 Receptor AgonistCAS: 1796565-52-0Purity: >99.50%
Orexin 2 Receptor Agonist is a potent (EC50 on OX2R is 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist.
- GC30832GSK1059865CAS: 1191044-58-2Purity: >99.50%
GSK1059865 is a potent orexin 1 receptor antagonist.
- GC30941Nemorexant (ACT-541468)CAS: 1505484-82-1Purity: >98.00%
Nemorexant (ACT-541468), a benzimidazole derivative, is an orally selective dual-orexin antagonist (DORA).
- GC36812Orexin B, human TFAPurity: >98.00%
Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC13539 | SB-334867 hydrochloride | 249889-64-3 | >98.00% | |
SB-334867 hydrochloride is a potent, selective, and blood-brain barrier-permeable orexin-1 (OX1) receptor antagonist, with pK b of 7.4 for OX1 and pK i values of 5.4 and 5.3 for 5-HT2B and 5-HT2C, respectively. | ||||
| GC15034 | SB-334867 | 792173-99-0 | >98.00% | |
SB-334867 is a potent, selective, and blood-brain barrier-permeable orexin-1 (OX1) receptor antagonist, with pK b of 7.4 for OX1 and pK i values of 5.4 and 5.3 for 5-HT2B and 5-HT2C, respectively. | ||||
| GC15317 | SB408124 | 288150-92-5 | >98.50% | |
OX(1)receptor antagonist | ||||
| GC17807 | TCS 1102 | 916141-36-1 | >99.50% | |
Antagonist for OX2 and OX1 receptors | ||||
| GC10549 | TCS OX2 29 | 372523-75-6 | >99.50% | |
OX2 receptor antagonist | ||||
| GC11818 | OXA (17-33) | 343268-91-7 | >98% | |
orexin OX1 receptor agonist | ||||
| GC12242 | MK 6096 | 1088991-73-4 | >99.00% | |
MK 6096 (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding). | ||||
| GC13741 | EMPA | 680590-49-2 | >99.50% | |
OX2 receptor antagonist | ||||
| GC14809 | JNJ 10397049 | 708275-58-5 | >98.50% | |
OX2 receptor antagonist | ||||
| GC14887 | Orexin B (human) | 205640-91-1 | >98% | |
Orexin B (human), a 28-residue peptides, has affinity for the OX1 and OX2 receptor with Ki of 420 and 36nM, respectively. | ||||
| GC15534 | SB-674042 | 483313-22-0 | >99.50% | |
A potent and selective orexin 1 receptor antagonist | ||||
| GC16336 | ACT 335827 | 1354039-86-3 | >98% | |
Orexin receptor 1 antagonist,potent and selective | ||||
| GC16540 | SB-408124 Hydrochloride | 1431697-90-3 | >98.00% | |
A potent orexin 1 receptor antagonist | ||||
| GC16745 | Orexin B (mouse) | 202801-92-1 | >98.50% | |
Orexin B (mouse) (Rat orexin B) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively. | ||||
| GC17992 | [Ala11,D-Leu15]-Orexin B | 532932-99-3 | >98% | |
[Ala11,D-Leu15]-Orexin B is a potent and selective orexin-2 receptor (OX2) agonist. | ||||
| GC19220 | Lemborexant | 1369764-02-2 | >99.50% | |
Lemborexant (E2006) is an oral active diorexin receptor antagonist (DORA) and has been approved by the US Food and Drug Administration for the treatment of insomnia. | ||||
| GC19249 | MK-1064 | 1207253-08-4 | >99.50% | |
MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. | ||||
| GC19250 | MK-3697 | 1224846-01-8 | >99.00% | |
MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM. | ||||
| GC19272 | Orexin 2 Receptor Agonist | 1796565-52-0 | >99.50% | |
Orexin 2 Receptor Agonist is a potent (EC50 on OX2R is 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist. | ||||
| GC19323 | SB-649868 | 380899-24-1 | >98% | |
SB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist (pKi =9.4 and 9.5 at the OX1 and OX2 receptor, respectively). | ||||
| GC30829 | IPSU | 1373765-19-5 | >98.00% | |
An orexin receptor 2 antagonist | ||||
| GC30832 | GSK1059865 | 1191044-58-2 | >99.50% | |
GSK1059865 is a potent orexin 1 receptor antagonist. | ||||
| GC30941 | Nemorexant (ACT-541468) | 1505484-82-1 | >98.00% | |
Nemorexant (ACT-541468), a benzimidazole derivative, is an orally selective dual-orexin antagonist (DORA). | ||||
| GC36812 | Orexin B, human TFA | - | >98.00% | |
Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively. | ||||
